DTL News

Posted by: Dave Fox
<  Back to news page

Dr Clive Roper and DTL

Clive graduated with a PhD in in vitro dermal metabolism and toxicology from Newcastle University. He joined Inveresk Research (acquired by Charles River in 2004) as a research officer to develop the in vitro skin penetration service. After serving in study director and scientific manager roles, he became Head of In Vitro Sciences in 2010 covering a wifde variety of testing services including skin absorption, routine regulatory in vitro toxicology, genetox and safety pharmacology.  Following some restructuring in 2020, Clive role changed to Director, In Vitro Toxicology, focussing on in vitro skin absorption, in vitro safety pharmacology, advanced in vitro 3D and tissue models and in vitro respiratory toxicology studies.

He has presented at many meetings and organized small meetings (Skin Metabolism) and large conferences (WC9). Clive has authored and co-authored many posters and abstracts as well as peer review papers. He is a peer reviewer for journals including TIV, Regulatory Pharmacology & Toxicology, Annals of Work Exposures, and Health and Skin Pharmacology and Physiology. He has been actively involved in advising regulatory agencies including NIH, SCCS and EPA as well as industry bodies and has presented a webinar on in vitro toxicology with the FDA. He was a founding member of the North American 3Rs Collaborative and services on the regulatory (MPS) subgroup. In 2021, Clive became a Member of the Board of the UK NC3Rs and left Charles River and set up his own consulting business, Roper Toxicology Consulting Limited.  He is most proud of having 4 peer review papers quoted in 2 OECD Test Guidelines (OECD 492 and 428) and working with US EPA, Health Canada, and other regulatory agencies towards ending the dermal triple pack and was acknowledged, along with the other panel members, in a recent paper published by the agencies on the subject.